# A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

> **NCT05221658** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 60 (estimated)

## Conditions studied

- ESCC or Esophageal Adenosquamous Carcinoma

## Interventions

- **DRUG:** HLX07+HLX10+ Cisplatin+5-FU
- **DRUG:** HLX07

## Key facts

- **NCT ID:** NCT05221658
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-25
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05221658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05221658, "A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05221658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*